<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601027</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-34315</org_study_id>
    <secondary_id>BRS0058</secondary_id>
    <nct_id>NCT02601027</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA</brief_title>
  <official_title>A Phase III Study of Pre-operative Transversus Abdominis Plane Blocks Using the Nimbus Ambulatory Infusion System in Patients Undergoing Abdominal Free Flap-based Breast Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine if pre-operative transversus abdominis plane (TAP)&#xD;
      nerve blocks by continued infusion of local anesthetic post-operatively affects&#xD;
      post-operative narcotic usage, as compared to a placebo TAP block, after breast&#xD;
      reconstruction surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: The primary objective is to determine if pre-operative transversus&#xD;
      abdominis plane (TAP) blocks with continued infusion of local anesthetic post-operatively&#xD;
      affect post-operative narcotic usage as compared to a placebo TAP block.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Determine if pre-operative TAP blocks with continued infusion of local anesthetic&#xD;
           post-operatively affect post-operative pain scores as compared to a placebo TAP block.&#xD;
&#xD;
        -  Determine if pre-operative TAP blocks with continued infusion of local anesthetic&#xD;
           post-operatively affect anti-emetic usage as compared to a placebo TAP block.&#xD;
&#xD;
        -  Determine if pre-operative TAP blocks with continued infusion of local anesthetic&#xD;
           post-operatively affect time to ambulation post-operatively as compared to a placebo TAP&#xD;
           block.&#xD;
&#xD;
        -  Determine if pre-operative TAP blocks with continued infusion of local anesthetic&#xD;
           post-operatively affect time to first bowel movement as compared to a placebo TAP block.&#xD;
&#xD;
        -  Determine if pre-operative TAP blocks with continued infusion of local anesthetic&#xD;
           post-operatively affect patient-reported quality of life as compared to a placebo TAP&#xD;
           block.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">September 7, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Narcotic Usage</measure>
    <time_frame>48 hours</time_frame>
    <description>Narcotic usage was collected for first 48 hours post-operatively after breast reconstruction. The type and amount of each narcotic administered were each converted to the morphine equivalent amount that would be orally administered to achieve the same event. This term is known as the oral morphine equivalent (OME). Narcotic usage was assessed between the group receiving transversus abdominis plane (TAP) nerve block compared to the group receiving the placebo control. The outcome is reported as the observed OME for each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative Pain Score</measure>
    <time_frame>2 days</time_frame>
    <description>Post-operative Pain Score is defined using Visual Analog Scale (VAS), a patient-reported pain score based on viewing a graphic of a scale 0 to 10, and indicating pain level. Each participant was asked about 48 hours after breast reconstruction to indicate their their perceived pain according on the VAS scale. Higher scores represent greater pain. The outcome is reported as the mean VAS score at 48 hours, with standard deviation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Anti-emetic Usage</measure>
    <time_frame>48 hours</time_frame>
    <description>Odansetron by intravenous administration was used to control nausea (ie, an anti-emetic drug). Anti-emetic usage was collected for first 48 hours post-operatively after breast reconstruction for the group receiving transversus abdominis plane (TAP) nerve block compared to the group receiving the placebo control. The outcome is reported as the mean quantity of Odansetron in milligrams (mg) administered to each group, with standard deviation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Time to ambulation is defined as the amount of time, from midnight on post-operative Day 1 (ie, first midnight following the surgery), to when the participant to be able to stand up and walk a few steps post-operatively. The assessment of whether or not the participant was able to walk was subjective on the part of the shift nurse (ie, no defined number of steps nor quantitative assessment of gait or stability), and was not explicitly defined in the protocol or elsewhere. The outcome is reported as the time to ambulation in days, with standard deviation, for the group receiving transversus abdominis plane (TAP) nerve block and the group receiving the placebo control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Bowel Movement</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Time to first bowel movement is defined as the amount of time, from midnight on post-operative Day 1 (ie, first midnight following the surgery), to when the participant was to be able to pass a stool post-operatively. The outcome is reported as the time in days, with standard deviation, for the group receiving transversus abdominis plane (TAP) nerve block and the group receiving the placebo control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measurement</measure>
    <time_frame>Pre-operative Baseline and Post-operative (2-6 months)</time_frame>
    <description>Quality of life for the study groups was assessed with the BREAST-Q questionnaire, a survey set of 6 pre-operative questionnaires comprised of 58 questions, and 15 post-operative questionnaires, collected 2 to 6 months after surgery, which is comprised of 109 questions. The results range for the pre-operative and post-operative questionnaire sets is 0 to 269 and 0 to 462, respectively. Because the baseline and post-operative domains are different, the BREAST-Q survey is not a measure of quality of life change over time. The Breast Q questionnaire was validated by Pusic, et al (citation provided). Higher scores for a domain represents better quality of life. The outcome is reported as the mean for each group and timepoint, with standard deviation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Breast - Female</condition>
  <arm_group>
    <arm_group_label>0.125% Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.125% bupivacaine infusion via transversus abdominis plane (TAP) catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion (sham) via transversus abdominis plane (TAP) catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transversus Abdominis Plane (TAP) block</intervention_name>
    <arm_group_label>0.125% Bupivacaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nimbus Infusion Pump IV Administration</intervention_name>
    <arm_group_label>0.125% Bupivacaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine infusion</intervention_name>
    <arm_group_label>0.125% Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
    <other_name>Marcaine</other_name>
    <other_name>Marcaine Spinal</other_name>
    <other_name>Sensorcaine</other_name>
    <other_name>Sensorcaine-MPF</other_name>
    <other_name>Sensorcaine-MPF Spinal</other_name>
    <other_name>ReadySharp bupivacaine</other_name>
    <other_name>P-Care M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetominophen</intervention_name>
    <arm_group_label>0.125% Bupivacaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <arm_group_label>0.125% Bupivacaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dilaudid</other_name>
    <other_name>Dilaudid-HP</other_name>
    <other_name>Exalgo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <arm_group_label>0.125% Bupivacaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Oxycontin</other_name>
    <other_name>Xtampza ER</other_name>
    <other_name>Oxaydo</other_name>
    <other_name>Roxicodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <arm_group_label>0.125% Bupivacaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Zofran</other_name>
    <other_name>Zofran ODT</other_name>
    <other_name>Zuplenz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Prior diagnosis or presumed diagnosis of breast cancer or undergoing prophylactic&#xD;
             treatment.&#xD;
&#xD;
          -  Greater than 18 years old.&#xD;
&#xD;
          -  Female.&#xD;
&#xD;
          -  Undergoing microsurgical breast reconstruction with abdominal free flap.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  True allergy to local anesthetics or opioids.&#xD;
&#xD;
          -  History of addiction to narcotics within the last 24 months&#xD;
&#xD;
          -  History of chronic pain on opioids within the last 24 months.&#xD;
&#xD;
          -  Specific mental health issues such as schizophrenia or bipolar disorder.&#xD;
&#xD;
          -  Patients who are pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon K Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mundy LR, Homa K, Klassen AF, Pusic AL, Kerrigan CL. Breast Cancer and Reconstruction: Normative Data for Interpreting the BREAST-Q. Plast Reconstr Surg. 2017 May;139(5):1046e-1055e. doi: 10.1097/PRS.0000000000003241.</citation>
    <PMID>28445351</PMID>
  </reference>
  <reference>
    <citation>Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009 Aug;124(2):345-353. doi: 10.1097/PRS.0b013e3181aee807.</citation>
    <PMID>19644246</PMID>
  </reference>
  <reference>
    <citation>Voineskos SH, Klassen AF, Cano SJ, Pusic AL, Gibbons CJ. Giving Meaning to Differences in BREAST-Q Scores: Minimal Important Difference for Breast Reconstruction Patients. Plast Reconstr Surg. 2020 Jan;145(1):11e-20e. doi: 10.1097/PRS.0000000000006317.</citation>
    <PMID>31577663</PMID>
  </reference>
  <results_reference>
    <citation>Kwong JW, Tijerina JD, Choi S, Shakir A, Nguyen DH, Nazerali RS, Lee GK. Randomized Double-Blinded, Placebo-Controlled Trial: Transversus Abdominis Plane (TAP) Blocks in Breast Cancer Patients Undergoing Reconstruction with Abdominal Free Flap. Annual Meeting of the California Society of Plastic Surgeons. San Diego, California. May 19, 2018.</citation>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <results_first_submitted>June 28, 2021</results_first_submitted>
  <results_first_submitted_qc>August 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2021</results_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Gordon Kwanlyp Lee</investigator_full_name>
    <investigator_title>Professor of Surgery (Plastic and Reconstructive Surgery)</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02601027/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.125% Bupivacaine</title>
          <description>0.125% bupivacaine infusion through transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Saline infusion (sham) for transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Registration to Surgery</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Surgery to Assessments</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.125% Bupivacaine</title>
          <description>0.125% bupivacaine infusion via transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline infusion (sham) via transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.24" spread="9.58"/>
                    <measurement group_id="B2" value="52.11" spread="10.50"/>
                    <measurement group_id="B3" value="51.11" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Narcotic Usage</title>
        <description>Narcotic usage was collected for first 48 hours post-operatively after breast reconstruction. The type and amount of each narcotic administered were each converted to the morphine equivalent amount that would be orally administered to achieve the same event. This term is known as the oral morphine equivalent (OME). Narcotic usage was assessed between the group receiving transversus abdominis plane (TAP) nerve block compared to the group receiving the placebo control. The outcome is reported as the observed OME for each group.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.125% Bupivacaine</title>
            <description>0.125% bupivacaine infusion through transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline infusion (sham) for transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Narcotic Usage</title>
          <description>Narcotic usage was collected for first 48 hours post-operatively after breast reconstruction. The type and amount of each narcotic administered were each converted to the morphine equivalent amount that would be orally administered to achieve the same event. This term is known as the oral morphine equivalent (OME). Narcotic usage was assessed between the group receiving transversus abdominis plane (TAP) nerve block compared to the group receiving the placebo control. The outcome is reported as the observed OME for each group.</description>
          <units>milligrams (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.3" spread="117.2"/>
                    <measurement group_id="O2" value="169.2" spread="136.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Pain Score</title>
        <description>Post-operative Pain Score is defined using Visual Analog Scale (VAS), a patient-reported pain score based on viewing a graphic of a scale 0 to 10, and indicating pain level. Each participant was asked about 48 hours after breast reconstruction to indicate their their perceived pain according on the VAS scale. Higher scores represent greater pain. The outcome is reported as the mean VAS score at 48 hours, with standard deviation.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.125% Bupivacaine</title>
            <description>0.125% bupivacaine infusion through transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline infusion (sham) for transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain Score</title>
          <description>Post-operative Pain Score is defined using Visual Analog Scale (VAS), a patient-reported pain score based on viewing a graphic of a scale 0 to 10, and indicating pain level. Each participant was asked about 48 hours after breast reconstruction to indicate their their perceived pain according on the VAS scale. Higher scores represent greater pain. The outcome is reported as the mean VAS score at 48 hours, with standard deviation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="1.72"/>
                    <measurement group_id="O2" value="3.96" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Anti-emetic Usage</title>
        <description>Odansetron by intravenous administration was used to control nausea (ie, an anti-emetic drug). Anti-emetic usage was collected for first 48 hours post-operatively after breast reconstruction for the group receiving transversus abdominis plane (TAP) nerve block compared to the group receiving the placebo control. The outcome is reported as the mean quantity of Odansetron in milligrams (mg) administered to each group, with standard deviation.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.125% Bupivacaine</title>
            <description>0.125% bupivacaine infusion through transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline infusion (sham) for transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Anti-emetic Usage</title>
          <description>Odansetron by intravenous administration was used to control nausea (ie, an anti-emetic drug). Anti-emetic usage was collected for first 48 hours post-operatively after breast reconstruction for the group receiving transversus abdominis plane (TAP) nerve block compared to the group receiving the placebo control. The outcome is reported as the mean quantity of Odansetron in milligrams (mg) administered to each group, with standard deviation.</description>
          <units>milligrams (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="5.30"/>
                    <measurement group_id="O2" value="9.93" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ambulation</title>
        <description>Time to ambulation is defined as the amount of time, from midnight on post-operative Day 1 (ie, first midnight following the surgery), to when the participant to be able to stand up and walk a few steps post-operatively. The assessment of whether or not the participant was able to walk was subjective on the part of the shift nurse (ie, no defined number of steps nor quantitative assessment of gait or stability), and was not explicitly defined in the protocol or elsewhere. The outcome is reported as the time to ambulation in days, with standard deviation, for the group receiving transversus abdominis plane (TAP) nerve block and the group receiving the placebo control.</description>
        <time_frame>up to 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.125% Bupivacaine</title>
            <description>0.125% bupivacaine infusion through transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline infusion (sham) for transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulation</title>
          <description>Time to ambulation is defined as the amount of time, from midnight on post-operative Day 1 (ie, first midnight following the surgery), to when the participant to be able to stand up and walk a few steps post-operatively. The assessment of whether or not the participant was able to walk was subjective on the part of the shift nurse (ie, no defined number of steps nor quantitative assessment of gait or stability), and was not explicitly defined in the protocol or elsewhere. The outcome is reported as the time to ambulation in days, with standard deviation, for the group receiving transversus abdominis plane (TAP) nerve block and the group receiving the placebo control.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.52"/>
                    <measurement group_id="O2" value="1.45" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Bowel Movement</title>
        <description>Time to first bowel movement is defined as the amount of time, from midnight on post-operative Day 1 (ie, first midnight following the surgery), to when the participant was to be able to pass a stool post-operatively. The outcome is reported as the time in days, with standard deviation, for the group receiving transversus abdominis plane (TAP) nerve block and the group receiving the placebo control.</description>
        <time_frame>up to 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.125% Bupivacaine</title>
            <description>0.125% bupivacaine infusion through transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline infusion (sham) for transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Bowel Movement</title>
          <description>Time to first bowel movement is defined as the amount of time, from midnight on post-operative Day 1 (ie, first midnight following the surgery), to when the participant was to be able to pass a stool post-operatively. The outcome is reported as the time in days, with standard deviation, for the group receiving transversus abdominis plane (TAP) nerve block and the group receiving the placebo control.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.08"/>
                    <measurement group_id="O2" value="1.62" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Measurement</title>
        <description>Quality of life for the study groups was assessed with the BREAST-Q questionnaire, a survey set of 6 pre-operative questionnaires comprised of 58 questions, and 15 post-operative questionnaires, collected 2 to 6 months after surgery, which is comprised of 109 questions. The results range for the pre-operative and post-operative questionnaire sets is 0 to 269 and 0 to 462, respectively. Because the baseline and post-operative domains are different, the BREAST-Q survey is not a measure of quality of life change over time. The Breast Q questionnaire was validated by Pusic, et al (citation provided). Higher scores for a domain represents better quality of life. The outcome is reported as the mean for each group and timepoint, with standard deviation.</description>
        <time_frame>Pre-operative Baseline and Post-operative (2-6 months)</time_frame>
        <population>Most participants were lost to follow-up, and did not return the case report form (CRF) for this patient-reported Quality of Life (QoL) data</population>
        <group_list>
          <group group_id="O1">
            <title>0.125% Bupivacaine</title>
            <description>0.125% bupivacaine infusion through transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline infusion (sham) for transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Measurement</title>
          <description>Quality of life for the study groups was assessed with the BREAST-Q questionnaire, a survey set of 6 pre-operative questionnaires comprised of 58 questions, and 15 post-operative questionnaires, collected 2 to 6 months after surgery, which is comprised of 109 questions. The results range for the pre-operative and post-operative questionnaire sets is 0 to 269 and 0 to 462, respectively. Because the baseline and post-operative domains are different, the BREAST-Q survey is not a measure of quality of life change over time. The Breast Q questionnaire was validated by Pusic, et al (citation provided). Higher scores for a domain represents better quality of life. The outcome is reported as the mean for each group and timepoint, with standard deviation.</description>
          <population>Most participants were lost to follow-up, and did not return the case report form (CRF) for this patient-reported Quality of Life (QoL) data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.30" spread="17.61"/>
                    <measurement group_id="O2" value="99.08" spread="20.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative (2 to 6 month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.11" spread="26.42"/>
                    <measurement group_id="O2" value="358.00" spread="16.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 7 days post-operative</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.125% Bupivacaine</title>
          <description>0.125% bupivacaine infusion through transversus abdominis plane (TAP) catheter&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline infusion (sham) for transversus abdominis plane (TAP) catheter.&#xD;
Transversus Abdominis Plane (TAP) block&#xD;
Nimbus Infusion Pump IV Administration&#xD;
Bupivacaine infusion&#xD;
Acetominophen&#xD;
Hydromorphone&#xD;
Oxycodone&#xD;
Ondansetron</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Localized Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Chest wall necrosis, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscle cramp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bullous dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gordon Kwanlyp Lee, Professor of Surgery (Plastic and Reconstructive Surgery)</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-5824</phone>
      <email>glee@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

